Effect of Thyrotropin Suppression Therapy on Bone in Thyroid Cancer Patients

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2015 Dec 15

PMID 26659220

Citations 14

Authors

Maria Papaleontiou

Sarah T Hawley

Megan R Haymart

Affiliations

Soon will be listed here.

Abstract

Background: The thyroid cancer incidence is rising. Despite current guidelines, controversy exists regarding the degree and duration of thyrotropin suppression therapy. Also, its potential skeletal effects remain a concern to physicians caring for thyroid cancer patients. We conducted a review of published data to evaluate existing studies focusing on the skeletal effects of thyrotropin suppression therapy in thyroid cancer patients.

Materials And Methods: A systematic search of the PubMed, Ovid/Medline, and Cochrane Central Register of Controlled Trials databases was conducted. The retained studies were evaluated for methodological quality, and the study populations were categorized into premenopausal women, postmenopausal women, and men.

Results: Twenty-five pertinent studies were included. Seven studies were longitudinal and 18 were cross-sectional. Of the 25 included studies, 13 were assigned an excellent methodological quality score. Three of 5 longitudinal studies and 3 of 13 cross-sectional studies reported decreased bone mineral density (BMD) in premenopausal women; 2 of 4 longitudinal studies and 5 of 13 cross-sectional studies reported decreased BMD in postmenopausal women. The remaining studies showed no effect on BMD. The only longitudinal study of men showed bone mass loss; however, cross-sectional studies of men did not demonstrate a similar effect.

Conclusion: Studies to date have yielded conflicting results on the skeletal effects of thyrotropin suppression therapy and a knowledge gap remains, especially for older adults and men. Existing data should be cautiously interpreted because of the variable quality and heterogeneity. Identifying groups at risk of adverse effects from thyrotropin suppression therapy will be instrumental to providing focused and tailored thyroid cancer treatment.

Implications For Practice: The standard treatment for thyroid cancer includes total thyroidectomy with or without radioactive iodine ablation, often followed by thyrotropin suppression therapy. Despite current guidelines, controversy exists regarding the degree and duration of thyrotropin suppression therapy, and discordant results have been reported on its adverse effects on bone. The present review provides physicians with existing data on the skeletal effects of thyrotropin suppression therapy, highlighting the need for further research to identify the groups at risk of adverse skeletal effects. This knowledge will aid in developing tailored thyroid cancer treatment.

Citing Articles

Hypothyroidism/subclinical hypothyroidism and metabolic dysfunction-associated steatotic liver disease: advances in mechanism and treatment.

Pu S, Zhao B, Jiang Y, Cui X Lipids Health Dis. 2025; 24(1):75.

PMID: 40016726 PMC: 11866868. DOI: 10.1186/s12944-025-02474-0.

Comparison of Bone Mineral Density and Trabecular Bone Score in Patients with and without Vertebral Fractures and Differentiated Thyroid Cancer with Long-Term Serum Thyrotrophin-Suppressed Therapy.

Hawkins Carranza F, Arroba C, Lopez Alvarez M, Librizzi S, Martinez Diaz Guerra G Diagnostics (Basel). 2024; 14(9).

PMID: 38732282 PMC: 11083193. DOI: 10.3390/diagnostics14090868.

Evaluation and Management of Bone Health in Patients with Thyroid Diseases: A Position Statement of the Korean Thyroid Association.

Hong A, Kang H Endocrinol Metab (Seoul). 2023; 38(2):175-189.

PMID: 37150514 PMC: 10164499. DOI: 10.3803/EnM.2023.1701.

Effect of thyrotropin suppressive therapy on lumbar bone mineral density in patients with differentiated thyroid cancer: a retrospective cohort study.

Wang X, Teng R, Liu F, Liu P, Yang Y Gland Surg. 2022; 11(2):432-441.

PMID: 35284311 PMC: 8899431. DOI: 10.21037/gs-22-50.

Understanding Worry About Risks Associated With Thyroid Hormone Therapy: A National Survey of Endocrinologists, Family Physicians, and Geriatricians.

Shah K, Reyes-Gastelum D, Gay B, Papaleontiou M Endocr Pract. 2021; 28(1):25-29.

PMID: 34438052 PMC: 8748409. DOI: 10.1016/j.eprac.2021.08.007.

References

Wang L, Smith A, Palmer F, Tuttle R, Mahrous A, Nixon I . Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma. Thyroid. 2014; 25(3):300-7. PMC: 6916125. DOI: 10.1089/thy.2014.0287. View

Chen C, Chen J, Yang B, Liu R, Tung S, Chien W . Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma. J Formos Med Assoc. 2004; 103(6):442-7. View

Marcocci C, Golia F, Vignali E, Pinchera A . Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine. J Bone Miner Res. 1997; 12(1):72-7. DOI: 10.1359/jbmr.1997.12.1.72. View

Gennari L, Bilezikian J . Osteoporosis in men. Endocrinol Metab Clin North Am. 2007; 36(2):399-419. DOI: 10.1016/j.ecl.2007.03.008. View

Roger P, Taton M, Van Sande J, Dumont J . Mitogenic effects of thyrotropin and adenosine 3',5'-monophosphate in differentiated normal human thyroid cells in vitro. J Clin Endocrinol Metab. 1988; 66(6):1158-65. DOI: 10.1210/jcem-66-6-1158. View

Ross D, Neer R, Ridgway E, Daniels G . Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. Am J Med. 1987; 82(6):1167-70. DOI: 10.1016/0002-9343(87)90219-1. View

Paul T, Kerrigan J, Kelly A, Braverman L, Baran D . Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women. JAMA. 1988; 259(21):3137-41. View

Marcocci C, Golia F, Vignali E, Pinchera A . Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women. J Clin Endocrinol Metab. 1994; 78(4):818-23. DOI: 10.1210/jcem.78.4.8157704. View

Toivonen J, Tahtela R, Laitinen K, Risteli J, Valimaki M . Markers of bone turnover in patients with differentiated thyroid cancer with and following withdrawal of thyroxine suppressive therapy. Eur J Endocrinol. 1998; 138(6):667-73. DOI: 10.1530/eje.0.1380667. View

10.

Karner I, Hrgovic Z, Sijanovic S, Bukovic D, Klobucar A, Usadel K . Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine. Eur J Med Res. 2005; 10(11):480-8. View

11.

Diamond T, Nery L, HALES I . A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocrinol Metab. 1991; 72(6):1184-8. DOI: 10.1210/jcem-72-6-1184. View

12.

Cauley J, Thompson D, Ensrud K, Scott J, Black D . Risk of mortality following clinical fractures. Osteoporos Int. 2000; 11(7):556-61. DOI: 10.1007/s001980070075. View

13.

Hawkins F, Rigopoulou D, Papapietro K, Lopez M . Spinal bone mass after long-term treatment with L-thyroxine in postmenopausal women with thyroid cancer and chronic lymphocytic thyroiditis. Calcif Tissue Int. 1994; 54(1):16-9. DOI: 10.1007/BF00316283. View

14.

Heijckmann A, Huijberts M, Geusens P, de Vries J, Menheere P, Wolffenbuttel B . Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma. Eur J Endocrinol. 2005; 153(1):23-9. DOI: 10.1530/eje.1.01933. View

15.

Guo C, Weetman A, Eastell R . Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine. Clin Endocrinol (Oxf). 1997; 46(3):301-7. DOI: 10.1046/j.1365-2265.1997.1280950.x. View

16.

Stepan J, Limanova Z . Biochemical assessment of bone loss in patients on long-term thyroid hormone treatment. Bone Miner. 1992; 17(3):377-88. DOI: 10.1016/0169-6009(92)90787-e. View

17.

Goldacre M, Roberts S, Yeates D . Mortality after admission to hospital with fractured neck of femur: database study. BMJ. 2002; 325(7369):868-9. PMC: 129634. DOI: 10.1136/bmj.325.7369.868. View

18.

Haugen B . 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed?. Cancer. 2016; 123(3):372-381. DOI: 10.1002/cncr.30360. View

19.

Franklyn J, Betteridge J, Daykin J, Holder R, Oates G, Parle J . Long-term thyroxine treatment and bone mineral density. Lancet. 1992; 340(8810):9-13. DOI: 10.1016/0140-6736(92)92423-d. View

20.

Lehmke J, Bogner U, Felsenberg D, Peters H, Schleusener H . Determination of bone mineral density by quantitative computed tomography and single photon absorptiometry in subclinical hyperthyroidism: a risk of early osteopaenia in post-menopausal women. Clin Endocrinol (Oxf). 1992; 36(5):511-7. DOI: 10.1111/j.1365-2265.1992.tb02254.x. View